A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma

Full Title

A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Progressive Lymphoma


Despite conventional therapies, such as chemotherapy and radiation therapy, the treatment of relapsed lymphoma remains challenging, with the disease persisting in many patients. The goal of this study is to evaluate the safety and potential anti-lymphoma effectiveness of CPI-0610 in patients whose lymphoma has persisted or returned despite treatment with standard therapy.

CPI-0610 is an investigational drug designed to inhibit cancer growth by blocking a group of proteins called BET proteins. These proteins are known to regulate the cellular levels of different proteins that promote cancer cell growth and survival. CPI-0610 is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have Hodgkin or non-Hodgkin lymphoma that has continued to grow despite prior therapy and for which no other effective standard treatments are available.
  • At least 2 weeks must have passed since completion of prior chemotherapy or radiation therapy, 4 weeks since antibody therapy, and 6 weeks since radioimmunotherapy and entry into the study.
  • Patients must be able to be walk and do routine activities for more than half of their normal waking hours.
  • This study is open to patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Anas Younes at 212-639-5059 or Amy Copeland at 212-639-6104.





Disease Status

Relapsed or Refractory